oru.sePublikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
CRIM1 is expressed at higher levels in drug-resistant than in drug-sensitive myeloid leukemia HL60 cells
Örebro universitet, Institutionen för hälsovetenskap och medicin. Clinical Research Center, Örebro University Hospital, Örebro; Sweden.
Department of Medicine, Örebro University Hospital, Örebro, Sweden.
Örebro universitet, Institutionen för hälsovetenskap och medicin. Department of Medicine, Örebro University Hospital, Örebro, Sweden.
Örebro universitet, Institutionen för hälsovetenskap och medicin.
2010 (engelsk)Inngår i: Anticancer Research, ISSN 0250-7005, E-ISSN 1791-7530, Vol. 30, nr 10, s. 4157-61Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Aim: The aim of this study was to explore possible differences in the mRNA expression levels of CRIM1, SMAD5, BMP4 and BMP7 in sensitive (S) and multidrug-resistant (R0.5) myeloid leukemia HL60 cells.

Materials and Methods: HL60S and HL60R0.5 cells were exposed to daunorubicin (DNR) or cytarabine (Ara-C).

Results: Baseline levels of CRIM1 were found to be 15-fold higher in HL60R0.5 than in HL60S. Sixteen hours of exposure to DNR resulted in a 5.6-fold increase in CRIM1 levels in HL60S. Exposure to either DNR or Ara-C resulted in modest increases in CRIM1 levels in HL60R0.5. Similarly, baseline levels of SMAD5 and BMP4 were higher in HL60R0.5 than in HL60S cells. Analysis of the drug SMAD5-resistance marker permeability-glycoprotein (Pgp) revealed that CRIM1 and Pgp exhibit a covariance pattern of expression.

Conclusion: This study demonstrated that CRIM1 is expressed at high levels in resistant leukemia cells, indicating that CRIM1 may play a role in drug-resistance.

sted, utgiver, år, opplag, sider
Athens, Greece: International Institute of Anticancer Research, 2010. Vol. 30, nr 10, s. 4157-61
HSV kategori
Identifikatorer
URN: urn:nbn:se:oru:diva-37784ISI: 000283914400040PubMedID: 21036735Scopus ID: 2-s2.0-78650228378OAI: oai:DiVA.org:oru-37784DiVA, id: diva2:756389
Tilgjengelig fra: 2014-10-17 Laget: 2014-10-15 Sist oppdatert: 2018-04-24bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

PubMedScopusFulltext

Personposter BETA

Prenkert, MalinUggla, BertilTidefelt, UlfStrid, Hilja

Søk i DiVA

Av forfatter/redaktør
Prenkert, MalinUggla, BertilTidefelt, UlfStrid, Hilja
Av organisasjonen
I samme tidsskrift
Anticancer Research

Søk utenfor DiVA

GoogleGoogle Scholar

pubmed
urn-nbn

Altmetric

pubmed
urn-nbn
Totalt: 483 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf